Peter Johannes Goedings

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignees: Synthon Biopharmaceuticals B.v., Yale University, Byondis B.v.. Active years: 2016-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Johannes Goedings. Retrieved from https://idiyas.com/inventor/peter-johannes-goedings

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 43(Granted Patents)

Company Filing History:

4 out of 11

Synthon Biopharmaceuticals B.v.

where one patent can have more than one assignee

Years Active: 2016-2022

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11382982 - Duocarmycin ADCs showing improved in vivo antitumor activity (2022-07-12),

2. 10603387 - Duocarmycin ADCs showing improved in vivo antitumor activity (2020-03-31),

3. 10092659 - Duocarmycin ADCs for use in treatment of endometrial cancer (2018-10-09),

4. 9427480 - Duocarmycin ADCs for use in treatment of endometrial cancer (2016-08-30),

5. 9421278 - Duocarmycin ADCS showing improved in vivo antitumor activity (2016-08-23),

Title: The Innovations of Peter Johannes Goedings

Introduction

Peter Johannes Goedings is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). With a total of five patents to his name, Goedings has focused on innovative treatments for various types of cancer.

Latest Patents

One of his latest patents involves duocarmycin-containing ADCs that demonstrate improved in vivo antitumor activity. This invention is aimed at treating human solid tumors and hematological malignancies that express HER2, including breast cancer, gastric cancer, and several others. Specifically, it addresses the treatment of triple-negative breast cancer (TNBC) and solid tumors with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. This advancement holds promise for enhancing therapeutic options for patients suffering from these challenging cancers.

Career Highlights

Throughout his career, Goedings has worked with prominent organizations such as Synthon Biopharmaceuticals B.V. and Yale University. His experience in these institutions has allowed him to collaborate on groundbreaking research and development projects in the biopharmaceutical sector.

Collaborations

Some of his notable coworkers include Willem Dokter and Gijsbertus Franciscus Maria Verheijden. Their collective expertise has contributed to the success of various projects and innovations in the field.

Conclusion

Peter Johannes Goedings exemplifies the spirit of innovation in the biopharmaceutical industry. His work on duocarmycin-containing ADCs represents a significant step forward in cancer treatment, showcasing his commitment to improving patient outcomes.

Profile summary based on public USPTO records.